AXIN1 and AXIN2 variants in gastrointestinal cancers  by Mazzoni, Serina M. & Fearon, Eric R.
Mini-review
AXIN1 and AXIN2 variants in gastrointestinal cancers
Serina M. Mazzoni a, Eric R. Fearon a,b,c,*
a Department of Human Genetics, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA
b Department of Internal Medicine, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA
c Department of Pathology, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA
A R T I C L E I N F O
Article history:
Received 10 July 2014
Received in revised form 8 September 2014
Accepted 10 September 2014
Keywords:
Wnt signaling
Beta-catenin
Colon cancer
Hepatocellular carcinoma
Gastric cancer
A B S T R A C T
Mutations in the APC (adenomatous polyposis coli) gene, which encodes a multi-functional protein with
a well-deﬁned role in the canonical Wnt pathway, underlie familial adenomatous polypsosis, a rare, in-
herited form of colorectal cancer (CRC) and contribute to the majority of sporadic CRCs. However, not
all sporadic and familial CRCs can be explained by mutations in APC or other genes with well-
established roles in CRC. The AXIN1 and AXIN2 proteins function in the canonicalWnt pathway, and AXIN1/2
alterations have been proposed as key defects in some cancers. Here, we review AXIN1 and AXIN2 se-
quence alterations reported in gastrointestinal cancers, with the goal of vetting the evidence that some
of the variants may have key functional roles in cancer development.
© 2014 Published by Elsevier Ireland Ltd.
Introduction
Somatic mutations in genes functioning in the canonical, or
β-catenin-dependent, Wnt pathway are found in approximately 90%
of colorectal cancers (CRCs) [1]. These mutations contribute to CRC
development by stabilizing the “free” signaling pool of β-catenin
via disruption of the “β-catenin destruction complex”, which in-
cludes the APC (adenomatous polyposis coli) [2–4], AXIN1 [5–7],
AXIN2 [8,9], and GSK3β proteins [10,11]. The most common de-
struction complex defects in CRCs are loss of function mutations
in the APC tumor suppressor gene, although a subset of CRCs have
CTNNB1mutations encoding amutant β-catenin protein that is likely
resistant to regulation by the destruction complex [12,13]. While
APC is the most frequently mutated Wnt pathway tumor suppres-
sor gene, both germline and somatic mutations in the AXIN1 or AXIN2
genes have been identiﬁed in a subset of CRCs and in several other
cancer types. Since the ﬁrst reports of AXIN1/2 mutations in cancer,
other studies have been completed and AXIN1/2 sequence poly-
morphisms in the general population have been better deﬁned. The
purpose of this review is to offer a comprehensive update of the re-
ported constitutional and somatic AXIN1 and AXIN2 sequence variants
described thus far. Previous publications addressing AXIN1/2 mu-
tations have reviewed selected variants and have sometimes used
different AXIN1/2 reference sequences, making it diﬃcult to compare
mutations in a comprehensive fashion. Additionally, since
the time of some prior publications, germline sequence variation
in control populations has been described in more detail [14]. In-
depth evaluation of previously reported and recently reported
AXIN1/2mutations with reference to consistently annotated AXIN1/2
amino acid sequences and the current list of known polymor-
phisms will lead to a better understanding of which AXIN1/2
sequence variants may confer functional consequences for cancer
development. While this review speciﬁcally addresses AXIN1/2mu-
tations in gastrointestinal (GI) cancers, a comprehensive table of
AXIN1/2 sequence alterations reported in non-GI cancers is shown
in Appendix: Supplementary Table S1.
The Wnt/β-catenin pathway
The canonical Wnt pathway regulates cell fate during develop-
ment and cellular homeostasis in adult tissues, and Wnt pathway
dysregulation is seen in many cancer types (reviewed in Anastas
and Moon) [15]. The canonical Wnt pathway transmits extracellu-
lar Wnt signals to the nucleus via effects on β-catenin levels and
localization [16]. In the absence of an activatingWnt ligand, a protein
complex assembles to phosphorylate β-catenin at multiple resi-
dues in its amino-terminal domain [12,13,17,18]. The phosphorylated
β-catenin is then recognized by a ubiquitin ligation protein complex
and subsequently targeted for degradation by the proteasome [19].
The APC, AXIN1, and AXIN2 proteins are thought to function in the
assembly of a β-catenin destruction complex. When an activating
Wnt ligand is present, the destruction complex is inhibited and the
free, signaling pool of β-catenin can translocate to the nucleus, where
β-catenin binds to TCF/LEF transcription factors to modulate the ex-
pression of target genes [16,20–22].
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AXIN1/2 protein function
There are two AXIN proteins: AXIN1 and AXIN2. In the case of
AXIN2, the mouse protein is also known as conductin and the rat
AXIN2 protein is also known as Axil. Axin1 was initially identiﬁed
as the locus responsible for a series of dominant “kinky” tail mouse
phenotypes, all resulting from spontaneous transposon insertions
into an exon of Axin1 [23]. When co-injected with Wnt pathway
components into the ventral side of Xenopus embryos, Axin1 mRNA
inhibits ectopic axis formation, identifying the protein as a nega-
tive regulator of Wnt signaling [24]. A primary function of AXIN1
in the Wnt pathway is in the assembly of the β-catenin destruc-
tion complex, thus inhibiting the expression of Wnt- and β-catenin-
dependent target genes. Aberrant activation of the Wnt pathway
is widely presumed to be amain driver of CRC. Hence, in part because
AXIN1 is a negative regulator of β-catenin levels and localization,
AXIN1 has been classically thought of as a tumor suppressor protein.
AXIN2 was initially identiﬁed based on its yeast-two-hybrid in-
teractions with β-catenin and GSK3β and named for its homology
to AXIN1 [8,9]. AXIN2, like AXIN1, acts as a scaffold to help assem-
ble the β-catenin destruction complex, and the two proteins show
high similarity to one another in several domains: the Tankyrase
binding domain which regulates AXIN protein stability via
PARsylation [25]; the RGS domain, which mediates binding to APC
[8]; the β-catenin-binding domain [8,9]; and the DIX domain, a di-
merization domain named for two proteins which share this motif
– Disheveled and AXIN1 [8,26–29]. Similar to AXIN1, AXIN2 nega-
tively regulates β-catenin-dependentWnt signaling. Injection of Axil
cDNA in Xenopus inhibits the axis duplication caused by activated
Wnt signaling, and dorsal cDNA injection results in ventralized
embryos [9]. These two AXIN proteins are considered functionally
equivalent, as an Axin2 cDNA rescues the Axin1-null lethality in the
mouse [30]. However, while the Axin1 knockout mouse is lethal in
embryogenesis at e9.5 [31,32], mice carrying homozygous null mu-
tations in Axin2 are viable and fertile, with only a mild skull
abnormality [33], providing proof that the two genes are not re-
dundant in vivo. This difference in phenotype is likely due to the
differential expression of the two genes [33]. The expression of AXIN1
is ubiquitous in various tissues [24], while AXIN2 shows a more re-
stricted developmental and cell-type-speciﬁc expression pattern
[9,24]. Uniquely, AXIN2, but not AXIN1, is a transcriptional target of
β-catenin-dependent Wnt signaling [34–36], and AXIN2 expres-
sion is elevated in cancers with activating Wnt pathway mutations.
Because of AXIN2’s positive regulation by upstream Wnt- and
β-catenin-dependent signals and because the AXIN proteins are the
least abundant members of the destruction complex, changes in
AXIN2 protein levels could be a key negative feedback mechanism
for the regulation of Wnt/β-catenin signaling in cells [37].
Colorectal cancer – germline mutations in AXIN1/2
Inactivating mutations in the APC gene are the most frequent
mechanism for activating theWnt pathway in CRCs, with about 80%
of CRCs harboring somatic APCmutations [1]. About 0.5–1.0% of CRCs
arise in individuals with familial adenomatous polyposis (FAP), who
carry an inactivating germline APC mutation [38]. Colon and rectal
adenomas and CRCs arise in those with FAP, in part, due to somatic
genetic or epigenetic inactivation of the remaining wild type APC
allele, leading to outgrowth of cells with no functional APC alleles
and dysregulated β-catenin levels. However, germline APC muta-
tions only account for a subset of the CRC cases with a hereditary
component. AXIN1 was analyzed as a candidate gene that might
harbor CRC-associated germline mutations in a set of 124 UK CRC
patients [39]. Several silent mutations were identiﬁed as well as
seven heterozygous, missense mutations in various exons. Four of
these mutations were found only in patients, while the other three
were also found in controls, but at lower frequencies. One of the
patient-speciﬁc mutations has also been described in CRC cell lines
[40] and is suggested to interfere with the interaction of AXIN1 and
GSK3β [41]. The four patient-speciﬁc mutations have since been
added to dbSNP, indicating that the variants are found in the general
population.
There are only three reported germline mutations in AXIN2 that
have been associated with CRC risk (see Table 1 for more detailed
information). The ﬁrst is a premature stop codon in exon 7 that was
found in a family with oligodontia (the absence of multiple adult
teeth) and a strong history of CRC [54]. The CRC phenotype in this
family was variable, and the age at CRC diagnosis for carriers ranged
from 27 to 64 years. A second report of a family with oligodontia
and a CRC risk found another premature stop codon, also in exon
7 (see Fig. 1) [55]. This family also had a variable cancer pheno-
type including one case of early-onset breast cancer. A third germline
Table 1
Summary of AXIN2 sequence alterations reported in GI cancers.
Sequence alteration identiﬁed* Cancer type Reference Notes
Insertions/deletions 52bp del delE745-S762 HB cell line D272 [42]
del1624 Exons 1–10 HB cell line HUH6 [42]
c.2010del12bp delT672-R675 CRC [43] MSS CRC
c.1925delA L688X CRC [44] MSI
c.1926insA E706X† CRC [45] MSI
c.1993delG L688X CRC [43] MSI
c.1994delG L688X CRC, GC [45] [46], [44], [47], MSI CRC and GC
c.1995insG E706X† CRC [45] [46], [44], MSI
c.2007delC L688X CRC [48] MSS
c.2011delC L688X CRC [45] MSI
c.2023delC L688X CRC [45] [44], MSI
Missense N412S‡ CRC [49] [50], Also seen in controls
R463C CRC [51] Germline, LOH wt allele
A603P†,‡ CRC [49] Germline, also seen in controls
R659W‡ HCC [52]
A695S‡ CRC [53]
S738F†,‡ CRC [49] Also seen in controls
S762N‡ CRC, HB cell line D165 [42] [49], Also seen in controls
Non-sense R656X CRC syndrome with oligodontia [54] Germline
W663X CRC syndrome with oligodontia [55] Germline
* Nucleotide and amino acid numbering modiﬁed to match modern sequences: NM_004655.3, NP_004646.3.
† These two mutations were found in the same individual, References [49] and [45] respectively.
‡ These variants are now listed in dbSNP (http://www.ncbi.nlm.nih.gov/SNP).
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AXIN2 mutation was found in a family with an apparently milder
form of familial polyposis, known as attenuated FAP [51]. Of note,
this family had no oligodontia or ectodermal dysplasia pheno-
type. The AXIN2 mutation in this third family was a missense
mutation in exon 5 with possible deleterious effects. However, the
role for this AXIN2 mutation in tumorigenesis seems quite uncer-
tain, as the mutant allele was lost in adenomas and polyps from the
proband and his sister. The three reported germline AXIN2 muta-
tions are heterozygous, suggesting that AXIN2 mutation could
perhaps predispose to cancer via a classical tumor suppressor model,
where the second allele is inactivated during tumor formation.
However, loss of the wild-type AXIN2 allele was not seen in the mis-
sense mutation family (third family) [51], and the state of the wild
type AXIN2 alleles has not been studied in cancer tissues from in-
dividuals carrying the two different AXIN2 nonsense mutations
[54,55]. It is also possible that the nonsense alleles could produce
truncated proteins with dominant or haplo-insuﬃcient effects.
A 2005 paper aimed to counter prior reports suggesting that con-
stitutional AXIN2 sequence variants play an important role in CRC
development. Speciﬁcally, the paper reported that analysis of 82 pro-
bands from families with hereditary CRC revealed 20 AXIN2 sequence
variants in 19 individuals [49]. Silent and intronic mutations were
ruled non-pathogenic and none of the identiﬁed missense muta-
tions were enriched in patient populations when compared to
controls. The authors thus concluded that germline AXIN2 muta-
tions are not associated with an increased CRC risk. While the
ﬁndings in this 2005 paper do not support a role for germline AXIN2
mutations in CRC risk, the collection of familial CRC cases studied
was moderate in size and none of the probands had oligodontia.
Another paper reporting on analysis of 31 patients with multiple
adenomas or CRC found two notable AXIN2 germline variants in a
single patient, but neither variant was clearly pathogenic based on
Polyphen analysis: T510T and N412S [50]. Both the T510T and N412S
AXIN2 alleles are now included in dbSNP.
Colorectal cancer – somatic mutations in AXIN1/2
Shortly after the identiﬁcation of a role for AXIN1 in the β-catenin
destruction complex, screening of AXIN1 for mutations in selected
patient samples and cell lines from various cancers was undertak-
en [40]. Two missense alterations were seen in the CRC cell lines
studied. The ﬁrst was S215L, found in the LS513 cell line, which also
exhibited loss of heterozygosity (LOH) of the wild type AXIN1 allele.
The second variant, L396M, was found in three cell lines: HCT-8,
HCT-15, DLD-1, and the authors chose to follow up on this alter-
ation because of the conservation of the affected amino acid and
its location in the GSK3β binding domain (see Fig. 2). Expression
of a fragment of the mouse Axin1 gene with an analogous muta-
tion indeed showed reduced binding to GSK3β, suggesting this
variant allele may have functional consequences on the ability of
the AXIN1 protein to regulate β-catenin. Because these variants were
identiﬁed in cell lines, with no matched normal DNA, it was unclear
if the AXIN1 variants are somatic mutations or germline polymor-
phisms. Both The S215L and L396M variants have since been listed
in dbSNP, likely suggesting that these variants represent germline
sequence variants, and not somatically acquired mutations.
A 2002 report comparing CRCs harboring mismatch repair
pathway (MMR) defects (so-called microsatellite instability-high or
MSI-H CRCs) versus CRCs with intact MMR (microsatellite-stable or
MSS CRCs) suggested that AXIN1 mutations may be important in
MSI-H CRCs [57]. Out of 33 MSI-H CRC samples studied, eight
somatic, missense mutations in AXIN1 were found in seven tumors.
No somatic mutations predicted to alter AXIN1 protein encoding
sequences were found in the MSS samples. In the MSI-H CRCs with
      * * * *  * * *
***** *** *** **** *** *** ***
AA Change:
Deletion: 
Frameshift: 
A 
B 
Germline  ( ) 
Somatic    (*) 
Alteration:         412         463       603         659          695         738         762
                     S           C         P           W            S           F           N
Human       …SEL---TLNSREGA…GRYSPRSRS…GAPGGAGALQL…GERASRHHLWGG…PPNTLAQLEEA…GATPFSNPSLA…HALQASELVVT…  
Chimp       …SEL---TLNSREGA…GRYSPRSRS…GAPGGAGALQL…GERASRHHLWGG…PPNTLAQLEEA…GATPFSNPSLA…HALQASELVVT…  
Mouse       …SEL---ALSSREGG…GRYSPRSRS…GAPGGAGVLQL…AERAGRHHLLGG…PPNTLAQLEEA…GATPFSNPGLA…HALQASELVVT…  
Dog         …SEQ---ALSSRDGA…GRYSPRSRS…GMSSAAGAPQL…GERVSRHHLLG-…PPNTLAQLEEA…GASPFANPSLA…HALQASELVVT…  
Chicken     …LELPASLQSSREMV…GRHSPRARS…GLPGPSG-VQL…SERPGRHHPWG-…PPNTLAQLEEA…GNTPFCNASLT…HTSQSSELVVT…  
Zebrafish   …SEM-----SSSSAS…LRHSPRSRS…------SLLQL…WGG-------GG…PPNTLAQLEEA…GSSAFP-----…HSSLGSETVVT…  
           :           -         .           -            :           -           :   
+ highly conservative change 
: conservative change 
. semi-conservative change 
- non-conservative change 
Fig. 1. Location and amino acid conservation of AXIN2 sequence alterations reported in association with GI cancers. (A) Diagram of the location of germline and somatic
AXIN2 variants implicated in GI cancers. The locations of important functional domains in AXIN2 are indicated. Missense and nonsense variants and deletions are shown
above the diagram, frameshifts are shown below. Note the density of frameshifts in the exon 7 mononucleotide repeats region. (B) Amino acid conservation of the missense
variants. Conservation designated by Gonnet [56] PAM 250 scores: > 1.5 (+), 0.5 to 1.5 (:), 0.5 to −0.5 (.), <−0.5 (−).
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AXIN1 somatic mutations, no LOH analysis was done. But, one tumor
did show two different AXIN1 mutations, potentially representing
selection for AXIN1 bi-allelic defects, perhaps akin to the situation
seen for some tumor suppressor genes. Another study of AXIN1
mutations in 54 CRC samples reported ﬁve missense mutations and
one nonsense mutation [58]. No matching normal tissue or blood
samples were available to determine if these were somatic or
germline changes. AXIN2 was not assessed in either study [57,58].
A study by Liu et al. reported that 11 of 45 MSI-H CRCs tested
had somatic mutations in AXIN2 [45]. All of the mutations were
frameshifts in exon 7 mononucleotide tracts that were predicted
to lead to premature stop codons in the AXIN2 open reading frame.
In 60 CRCs with intact MMR, none contained an exon 7 AXIN2 frame-
shift. Only two of the eleven MMR-defective CRCs with AXIN2
frameshifts showed loss of the wild-type allele, not unexpectedly
because LOH is infrequent throughout the genome of MMR-
defective CRCs [59]. Assuming the remaining AXIN2 allele was not
silenced by epigenetic mechanisms in the remaining 9 of the 11
MMR CRCs with a frameshift mutation in one allele, the absence
of demonstrable bi-allelic AXIN2 defects suggests that if the AXIN2
variants were key in promoting colorectal tumorigenesis, theymight
have done so via dosage-dependent effects and/or through some
potential gain-of-function of the truncated AXIN2 proteins encoded.
The authors did not rule out nonsense-mediated decay for AXIN2
transcripts with premature stop codons. Of some interest, they did
show that overexpression of a truncated AXIN2 protein, predicted
to result from the frameshifts, promoted β-catenin accumulation
in cells in culture, consistent with a possible gain-of-function role
for the truncated AXIN2 protein.
In an analysis of 39 sporadic MSI-H CRCs, frameshifts at c.1994
or c.1995 in the exon 7 polyG-tract of AXIN2 were found in eight
tumors [46]. The connection between AXIN2 exon 7 frameshifts and
MMR-deﬁcient CRCs was further supported by a study of 310 CRCs
[44]. Sequencing of exon 7 revealed heterozygous frameshift
*
AA Change:
Indel: 
A 
B 
Missense  ( ) 
Nonsense ( ) 
Alteration:      59        101,103,106        122         203         215         263         
                  M           P M  R           A           M           L           T       
Human       …GIKGETSTATP…QDGISLFRTFLKQEGC…FWFACTGFRKL…YPSFLKSDIYLEYTRTGSESPKV…GRDAAPPGRLP… 
Chimp       …GIKGETSTATP…QDGISLFRTFLKQEGC…FWFACTGFRKL…YPSFLKSDIYLEYTRTGSESPKV…GRDAAPPGRLP… 
Mouse       …SIKSETSTATP…QDGISLFRTFLKQEGC…FWFACSGFRKL…YPSFLKSDIYLEYTRTGSESPKV…GRDPLPPSRLT… 
Dog         …GVKGETSAATP…QDGINLFRTFLKQEDC…FWFACSGFRKL…YPSFLKSDIYLEYTRTGSESPKL…GRDPAPPGRLT… 
Chicken     …AVRNETSTATP…QDGINLFRTFLKQEDC…FWFACSGFRKL…YPLFLKSDIYLEYTRTGGESPKI…SRDSAPSSRLT… 
Zebrafish   …SLKNEASIATP…QDGIHLFRTFLKQEEC…FWFACSGFRKQ…YPLFLKSDIYLEYTRTGGESPKL…ESDPTPSNRLT… 
                  -           - -  -           :           -            -          .       
Alteration:    307           345,349,353      394,395,396      411    418    425         495     
                K             L   H   H           NCM           D      I      S           E      
Human       …NPYYVNAGYAL…VDGIPPYRIRKQHRREMQE…AEELIHRLEAVQR…EEKLEERLKRVRMEEEGEDGDPSSG…-HRSPDSGHVA… 
Chimp       …NPYYVNAGYAL…VDGIPPYRIRKQHRREMQE…AEELIHRLEAVQR…EEKLEERLKRVRMEEEGEDGDPSSGP-HRSPDSGHVA… 
Mouse       …NPYYVNSGYAL…VDGIPPYRIRKQHRREMQE…AEELIHRLEAVQR…EEKLEERLKRVRMEEEGEDGEMPSGP-HRSPDSGHVA… 
Dog         …HPYYVSSGYAL…VDGIPPYRIRKQHRREMQE…AAELIHRLEAIQR…EEKLEERLKRVRMEEEGEDGDVPSGP-HRSPDNAHVP… 
Chicken     …NPYYVNTGYAM…IDGIPPYRLRKQHRREMQE…AAELINRLEEVQK…EEKLEERLKRVRAEEEGEDADISSGPMPRSPESGHLG… 
Zebrafish   …NPYYVNSGYAL…VDGVPPYRYRKPHRREIHE…AAELISRLEGVLR…QEKLEERLKRVRLEEEGDDADISTGPLSRSPDGLPAG… 
                :             -   :   :           :-+           +      +      .           +      
Alteration:      583         650         841    848 852     
                  S           S           Q      L   G
Human       …YSESVGAAPNA…RHRRTGHGS-S…VFEEVREDEAVLPVFEEKIIGK 
Chimp       …YSESVGAAPNA…RHRRTGHGS-S…---------------------- 
Mouse       …YSENAGTTLSA…RHRKAGHGS-S…VFEEVREDEAVLPVFEEKIIGK 
Dog         …HSESVGAAPNA…RHRKAGHGS-S…VFEEVREDEAVLPVFEEKIIGK 
Chicken     …YSENLGMAPVP…RHKKTNHGS-S…VFEEVREDDTILPIFEEKIIGK 
Zebrafish   …YADGMSVGPNT…RYKRGPYGSIS…VFEEVREDDAILPIFEEKIIGK 
                  .           .           :      -   - 
+ highly conservative change 
: conservative change 
. semi-conservative change 
- non-conservative change 
Fig. 2. Location and amino acid conservation of AXIN1 sequence alterations reported in association with GI cancers. (A) Diagram of the location of germline and somatic
AXIN1 variants implicated in GI cancers. The locations of important functional domains in AXIN1 are indicated. Missense and nonsense mutations are shown above the
diagram, insertions and deletions are shown below. (B) Amino acid conservation of the reported missense variants. Conservation designated by Gonnet [56] PAM 250 scores:
> 1.5 (+), 0.5 to 1.5 (:), 0.5 to −0.5 (.), <−0.5 (−).
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mutations in seven tumors, all of which were MSI-H. Four of the
seven tumors also had APC mutations, perhaps raising some un-
certainties about whether the AXIN2 frameshift mutations were
functionally signiﬁcant in CRC development or just a potential marker
of the MMR-defective phenotype. Finally, a survey of AXIN2 se-
quence alterations in sporadic CRCs and some CRC cell lines identiﬁed
several silent mutations, one 12-bp in frame deletion (del2013-
2024), and potentially pathogenic frameshift mutation (1993del1G),
which led to a premature stop at L688X [43]. This frameshift was
seen in tumors with or without APC mutation, but only in MSI-H
cancers, as reported previously [45]. The 12-bp deletion occurred
in aMSS tumor and resulted in the in-frame loss of four amino acids,
including two potential phosphorylation sites [43].
A study of a Kashmiri population looking for AXIN1/2 muta-
tions in CRCs found two previously reported AXIN2 single nucleotide
polymorphisms and a novel missense variant A695S [53]. The three
patients with this sequence variant were diagnosed at ages 50, 57,
and 65 and all presented with well-differentiated tumors with LOH
of the DCC region.While the authors reported using adjacent normal
tissue in their analysis, this variant has since been included in dbSNP,
and because it was found in 6% of the patients, it is likely a germline
polymorphism.
In addition to somatic sequence changes, changes in AXIN2 ex-
pression have been proposed as a potential contributing factor in
CRC progression [48]. In a study of gene expression data, AXIN2 ex-
pression was signiﬁcantly reduced in MSI-H CRCs compared to MSS
cases. Of note, the AXIN2 gene is directly regulated by the Wnt/β-
catenin pathway, and elevated AXIN2 expression is observed in most
CRCs with APC mutations or other canonical Wnt pathway defects.
Consistent with the gene expression data, the AXIN2 promoter was
found to be hypermethylated in 10 out of 27 MSI-H samples, but
in none of theMSS samples. Additionally one of the nineMSI-H CRCs
with AXIN2 promoter hypermethylation had a frameshift leading
to a premature stop codon (L688X). Ectopic expression of AXIN2 in
an MSI-H CRC cell line with low levels of endogenous protein re-
sulted in inhibition of cell growth, suggesting that AXIN2 may act
as a tumor suppressor inMSI-H CRCs [48]. A second study also found
AXIN2methylation and reduced expression in MSI-H CRCs [60]. The
authors reported that AXIN2 expression was correlated with certain
clinical and pathological features of sessile serrated adenomas, a
colon cancer precursor lesion distinct from typical adenomas. These
studies suggest that the level of AXIN2 proteinmay indeed have con-
sequences for cancer development.
Hepatocellular carcinoma (HCC) and hepatoblastoma (HB)
Germline mutations in APC are associated with an increased risk
of HB, suggesting other components of the Wnt pathway may be
important in HB tumorigenesis [61]. Sequencing of the AXIN1 gene
in 22 HBs revealed eight exon variants, seven of which were silent
[62]. The eighth variant, T58M, was also found in peripheral blood,
so it may be a potentially benign polymorphism. A second study
of sporadic HB tumors and HB cell lines found two large, out of frame
deletions (52-bp and 1624-bp) and one somatic, missense muta-
tion (S762N) in AXIN2 [42] that has since been added to dbSNP.
HCCs frequently display activated Wnt signaling, but often lack
mutations in CTNNB1 or APC; hence, the AXIN1 gene was screened
for mutations. Out of 100 primary HCCs studied, six AXIN1 altera-
tions were found in ﬁve tumors, including three deletions and three
premature stop codons [63]. In three of the four AXIN1-mutant
tumors that could be fully analyzed, LOH of the wild type AXIN1
allele was seen. Out of six HCC cell lines, two were found to contain
deletions in both AXIN1 alleles. The authors then investigated the
AXIN1 alterations in HCC lines for dysregulated Wnt signaling and/
or cell proliferation. One of the two AXIN1-mutant HCC cell lines
showed increased β-catenin reporter activity, and, in all six cell lines,
overexpression of AXIN1was growth suppressive. The authors there-
fore concluded that AXIN1 may act as a tumor suppressor in HCC.
Further analysis of HCC and HB has revealed some additional al-
terations in AXIN1 and AXIN2 [52]. While no AXIN2 variants were
seen in 27 HBs, two AXIN1 missense variants were found (G650S
and R841Q). Both of these sequence variants have since been added
to dbSNP with minor allele frequencies of 0.0147 and 0.0101, re-
spectively. Even though the authors stated that they used matched
normal samples to speciﬁcally identify somatic alterations, it is pos-
sible that the reported variants were just germline polymorphisms.
In a study of 73 HCCs, seven somatic variants were found in AXIN1:
ﬁve missense alterations, one 12-bp insertion, and a 1-bp deletion
leading to a premature stop codon. LOH of the wild type AXIN1 allele
was seen in four of the ﬁve AXIN1-mutant HCCs tested, further sup-
porting a role for AXIN1 as a tumor suppressor in HCC. In this same
collection of 73 HCCs, two AXIN2 sequence changes were identi-
ﬁed, both in exon 7: a missense mutation (R659W) and a 12-bp
deletion (del2013-2024). The 12-bp deletion has since been iden-
tiﬁed in many other cancer types, and the missense allele has been
included in dbSNP.
Gastric carcinoma
Because of the highly mutable mononucleotide repeats present
in AXIN2, one study looked for exon 7 AXIN2 alterations in gastric
cancers with MSI [47]. Nine of the 60 cancers had an AXIN2 frame-
shift mutation, and all of the cancers with an AXIN2 mutation were
MSI-H.
Discussion
The potential tumor suppressor function of the AXIN1 and AXIN2
proteins has long been hypothesized, based largely on their roles
in the β-catenin destruction complex. However, the importance of
the AXIN proteins, in vivo, for the inhibition of tumor develop-
ment or progression is not well established, and the functional
consequences of AXIN1 or AXIN2mutations in cancer remain largely
undeﬁned. While many of the reported AXIN2 mutations cluster in
one region of the gene, AXIN1 mutations are more dispersed with
no clear preference for certain sequence features or functional
domains. Maps of the AXIN1 and AXIN2 mutations discussed above
are shown in Figs. 1 and 2, along with a prediction of the function-
al conservation for the missense alleles. Some reported AXIN1/2
mutations can be deemed non-contributory in cancer develop-
ment, based on the lack of a clear link to familial cancer
predisposition or because the variants are present at similar fre-
quencies in controls. As noted in Table 2, many of the AXIN1
mutations reported in cancers have since been added to the dbSNP
database or identiﬁed in the 1000 Genomes Project. Further studies
to compare allele frequencies in control and patient populations
could shed light on whether these polymorphisms have any cancer
signiﬁcance. Other reported mutations need to be more thor-
oughly tested in clinical samples, human populations, and in cell
culture and animal models to determine if they are functionally sig-
niﬁcant. Studies that address the loss of both alleles of AXIN1 or
AXIN2 versus mutation of one allele in patient samples or animal
models could help to clarify if AXINs function as classic “two-hit”
tumor suppressor genes, or if the mutant alleles have a dominant
effect in cancer development. A recent study found that complete
loss of Axin1 has a role in predisposition to liver cancer in a mouse
model [64]. Combined with AXIN1 somatic inactivating mutations
and LOH in HCCs, these data strongly support a role for AXIN1 as a
tumor suppressor in HCC.
In addition to the many AXIN2 mutations reported in various
cancer types, a few reports have linked AXIN2 SNPs to the disease
risk in breast and lung cancers [65–67]. Further efforts may support
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the role of AXIN2 variant alleles in cancer predisposition and perhaps
might uncover some value for the variants in informing approaches
for the prevention or early diagnosis of cancer. The vast majority
of the AXIN2 mutations in cancer have been found in exon 7 and
many are frameshifts, as highlighted in Fig. 1. Because the frame-
shift mutations are present in highly mutable mononucleotide tracts
and because the mutations arise in MMR-defective CRCs, it is dif-
ﬁcult to determine whether these frameshifts, which lead to
premature stop codons, play a role in cancer development or pro-
gression, or whether they are passenger mutations. The association
with a major tooth phenotype and a very strong predisposition to
colon and perhaps other cancers in some individuals carrying het-
erozygous, germline, truncating AXIN2 mutations strongly suggests
that these mutant alleles may have major contributing roles in de-
velopment and in cancer predisposition. Because the tooth phenotype
is constitutional, it could inform on the function of these germline,
truncatingmutations. However, the role of theWnt pathway in tooth
development is complex and the tooth defect in these two fami-
lies affects the development of a subset of secondary teeth, which
cannot be easily modeled in the mouse. Nonetheless, it is interest-
ing to note that some FAP patients (carrying heterozygous APC
germline mutations) will develop extra teeth and benign odonto-
mas [68]. If we assume that the APC mutations lead to activation
of Wnt signaling, then the reduction in teeth in AXIN2mutation car-
riers suggests that the AXIN2 mutant alleles might not be simple
loss of function alleles, or perhaps AXIN2 plays an important role
outside the β-catenin destruction complex. Further studies of the
function of the wild type and mutant AXIN2 proteins may yield im-
portant clues into AXIN2 function in development and cancer.
If the AXIN proteins are indeed important suppressors of cancer
development or progression, then small molecules that stabilize these
proteins, such as the tankyrase inhibitor XAV939, could be valu-
able treatment strategies [25]. While some ﬁndings suggest that
increased levels of AXIN proteins inhibit colon cancer cells that are
dependent on β-catenin signaling, a recent mouse study suggests
the opposite: that high levels of AXIN2 actually promote cancer cell
invasion and perhaps metastasis [69]. Additionally, the AXIN pro-
teins have been reported to be involved in multiple non-canonical
signaling pathways, including the Ras/ERK [70,71] and SAPK/JNK
pathways [72], so it will also be valuable to assess if any of the re-
portedmutations in AXIN1/2 could promote tumorigenesis via a non-
β-catenin dependent mechanism. Without clear evidence of the
pathogenicity of the mutations identiﬁed to date or strong evi-
dence from animal models, the importance of AXIN1 and AXIN2 as
tumor suppressor genes or oncogenes in cancer and the potential
role of the variants in non-Wnt pathway functions remain unre-
solved issues of keen interest.
In closing, many AXIN1/2 sequence variants in cancer have been
reported. The evidence for AXIN1 as a possible tumor suppressor
gene in a subset of HCCs is generally convincing, based on se-
quence analyses, tissue culture work, and mouse model studies.
However, evidence supporting the functional signiﬁcance of AXIN1
mutations in other human cancer types is inconclusive or lacking
at this point. The rare germline AXIN2 mutations that have been as-
sociated with oligodontia and predisposition to colon and possibly
other cancers provide intriguing evidence of a role for AXIN2 mu-
tations in CRC development. The causal signiﬁcance of the somatic
AXIN2 frameshift mutations in mononucleotide repeats seen in a
Table 2
Summary of AXIN1 sequence alterations reported in GI cancers.
Sequence alteration identiﬁed* Cancer type Reference Notes
Insertions/deletions Deletion of exons 1–2 HCC cell line: SNU475 [63] Homozygous, no transcript detected
Deletion of exon 4 HCC cell line: Alexander [63] Homozygous
13bp deletion Codons 346–350 HCC cell line: SNU423 [63] LOH of second allele
5-bp deletion Codon 386 HCC [63]
13-bp deletion Codons 444–448 HCC [63]
25-bp deletion† Codons 485–493 HCC [63]
c.1076del1bp M418X HCC [52]
c.1714ins12bp Insert: QVHH HCC [52]
Missense T58M HB [62] Germline
L101P† CRC [57] MSI CRC, heterozygous
R103M CRC [57] MSI CRC, heterozygous
L106R HCC [52]
T122A CRC [57] MSI CRC, heterozygous
K203M‡ CRC [58]
S215L‡ CRC cell line: LS513 [40]
P263T‡ CRC [39] Heterozygous
N307K CRC [58]
P345L HCC [52]
R349H‡ CRC [39] Heterozygous
R353H† CRC [57] MSI CRC, heterozygous
H394N CRC [58]
R395C CRC [57] MSI CRC, heterozygous
L396M‡ CRC, CRC cell lines: HCT-8, HCT-15, DLD-1 [39] [40], Heterozygous [39]
E411D CRC [57] MSI CRC, heterozygous
M418I CRC [57] MSI CRC, heterozygous
G425S‡ HCC [52]
D495E‡ CRC [39] Heterozygous
G583S CRC [57] MSI CRC, heterozygous
G650S‡ HB, HCC, CRC [52] [39],
R841Q‡ HB, CRC [52] [39], Heterozygous [39]
P848L CRC [58]
E852G CRC [58]
Non-sense W247X HCC [63]
Y305X CRC [58]
E406X† HCC [63] Seen in 2/100 cases
* Nucleotide and amino acid numbering modiﬁed to match modern sequences: NM_003502.3, NP_003493.1.
† These two mutations were found in the same individual, References [63] and [57] respectively.
‡ These variants are now listed in dbSNP (http://www.ncbi.nlm.nih.gov/SNP).
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subset of MSI-H cancers is unclear as the mutations may simply
reﬂect the MSI-H phenotype. Further functional studies are needed
to deﬁne the roles of the AXIN1 and AXIN2 proteins in regulating
the Wnt and other signaling pathways in context- and tissue-
dependent fashions, as well as to deﬁne themeans by whichmutant
AXIN1 and AXIN2 alleles may contribute to cancer development and
progression via classic loss-of-function (“two-hit”) mechanisms,
dosage-dependentmechanisms, and potentially even dominant gain-
of-function mechanisms.
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